W STRATEGIES, LLC for CALIFORNIA LIFE SCIENCES
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
March 2016 CMS proposed rule implementing a new Part B drug payment model. H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
Promoted life sciences community and communicated economic and health benefits of the industry. S.1878: Advancing Hope Act of 2016 - "To extend the pediatric priority review voucher program". H.R. 6: 21st Century Cures Act and Senate HELP Committee Innovation effort to promote medical innovation for patients, specifically with respect to reforms at NIH. Education about need for incentives for antibiotic development. S.524: Comprehensive Addiction and Recovery Act of 2016, as it relates to Rx take back programs. Education about the value of innovative new medicines. Education about FDA performance on review of drugs and medical devices. H.R.3299: Strengthening Public Health Emergency Response Act of 2015.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.